Decriminalization of Psilocybin Mushrooms, in all 50 states

[אל תשאלו]

Decriminalization of Psilocybin Mushrooms, in all 50 states

Benefits of magic mushroom therapy long lasting

Written on July 3, 2008.

Nature News
July 3, 2008

Patients given psilocybin report continued well-being a year later.
The psychedelic ingredient of magic mushrooms could help manage patients' anxiety.
The benefits for people who have had positive or even mystical experiences induced by the psychedelic drug psilocybin the psychoactive ingredient in magic mushrooms linger for as much as a year, according to the latest follow-up study of such patients.
The study offers more support to those who argue that, when used responsibly, some drugs more commonly taken for leisure can safely be used to relieve the stress associated with severe chronic diseases such as cancer.
This experience has a compelling meaningfulness and spiritual component to it that is strongly conserved over time, argues the study's lead author, Roland Griffiths of the Johns Hopkins University School of Medicine in Baltimore.
Although only a single dose was administered to the 36 patients in the original study, they reportedly still considered the experience to have valuable after-effects at the time of the follow-up study.
A clutch of new studies using psilocybin are now planned or under way in the United States, hoping to alleviate cancer-related anxieties with only one dose that has a lasting, positive outcome for patients.
Sustained change
The latest study, published in the Journal of Psychopharmacology1, is a follow-up to a 2006 experiment in which Griffiths and colleagues gave high doses of psilocybin to 36 'spiritually inclined' volunteers who had never previously taken hallucinogens2. The participants were encouraged to focus their attention inward during their experience, and two months later many reported sustained, positive changes in their lives.
Realization of unity of existence and relativity of ordinary consciousness I have had glimpses of this before but this was profound and sustained, read one participants comments on the experience. Another remarked that, it was so awesome to be with God [that] words cant describe the experience. psilocybin patientPatients in psilocybin trials report continued benefits a year later.R. Griffiths et al.
Previous studies have shown a similar effect, most famously the Good Friday Experiment of 1963 in which theology students were given psilocybin in a church. However, this experiment was not peer-reviewed, and many studies completed in the 1960s were often inadequately followed up. Griffiths was keen use measures adapted from modern studies to see if the life-enhancing qualities people described in 2006 still persisted. Mystical experience
Of the original 22 participants who had a complete mystical experience as defined by the Pahnke-Richards Mystical Experience Questionnaire, all but one still satisfied the same criteria 14 months later.
Most volunteers who had the mystical experience continue to endorse the same extent of positive changes in attitude, altruistic behaviour and mood," says Griffiths.
After 14 months, 67% of the participants rated the treatment as one of the five most spiritually significant moments of their lives, and 17% rated it as their single most spiritually profound experience. In addition, 64% of subjects reported that their sense of well-being or life satisfaction increased.
Griffiths says it is uncommon in psychopharmacology for a positive effect to last so long after a single dose.
However, the study is based on a retrospective questionnaire and a sample of already spiritually inclined people. Griffiths admits there is bias in the data, but says he is looking forward to moving on to more powerful prospective studies. This opens up a host of scientific questions and therapeutic applications.
But not everyone agrees that psychedelics have a place in medicine. Griffith Edwards, emeritus Professor of addiction research and co-founder of National Addiction Centre, says that while he respects the studies authors and their conclusions it must be remembered that such drugs can have serious bad effects as well as good ones. "People can have self-destructive and suicidal thoughts as well as mystical experiences," he says. Edwards add that he is worried about this being taken as a trigger for a new campaign for the medical profession. "There are other ways of helping people," he says. Improved mood
Nevertheless, Charles Grob, a professor at the University of California, Los Angeles School of Medicine, recently finished treating his final patient in a study using psilocybin to treat cancer anxiety. He says studies on terminal cancer patients in the 1950s and 1960s found that those subjects who had a transcendent or transpersonal experience during their psychedelic treatment session also had the most dramatic subsequent reduction in anxiety, improved mood and better overall quality of life.
The study provides a feasible treatment model for clinical conditions that are considered very difficult to treat, says Grob. Psychedelics, when utilized by capable facilitators under optimally safe conditions, may very well achieve therapeutic breakthroughs with what is often considered to be an extremely resistant and unresponsive patient population.
Griffiths and his team have also published some proposed guidelines3 for the safe clinical use of hallucinogens. We believe this research now can proceed safely but it should be done cautiously, says Griffiths. Were eager that it not be disrupted again like it was for the last 40 years because scientifically there is so much promise in having this research move forward.
Griffiths is currently recruiting subjects for a study using psilocybin to treat cancer anxiety, which will be conducted at the Johns Hopkins University School of Medicine where he is based.


There have been many studies over the years supporting the benefit of psilocybin, the psychoactive chemical occurring naturally in some mushrooms.

The most authoritative study yet was published this week by a team from Johns Hopkins School of Medicine, according to GOOD:

A team from the Johns Hopkins University School of Medicine recently published results from a roughly year-long experiment. The researchers worked with 18 volunteers who were given pure psilocybin to measure how it affected people and how different dosages changed the experience. The subjects were screened for psychological health and given the drug in a pleasant environment, after preparatory guidance. They even had a soundtrack consisting of "classical and world music chosen to complement the arc of the psilocybin action, from onset, through the peak of the effects, and subsiding back to baseline."

The results? At high dosages people occasionally experienced fear, anxiety, or delusions. But the negative effects of those "bad trips" were easily mitigated by the reassuring researchers and didn't outlast the session. At more moderate doses, the results were almost unambiguously positive. Moreover, people didn't just appreciate the experience as fun; they found it spiritually meaningful, with lasting benefits. - Buisness Insider

Summary: The New Yorker interviews psilocybin researchers and study participant Eddie Marritz about how psilocybin-assisted psychotherapy may help reduce anxiety associated with terminal cancer diagnoses. Marritz speaks about using psilocybin as an adjunct to psychotherapy, and the members of the New York University psilocybin research team speak about the scientific importance of psychedelic research. "Preparation, the experience, and the integration of what happened contribute to it being powerful," explains psilocybin researcher Jeffrey Guss, M.D. "It isn't just in the molecule itself.”

The way in which we commonly perceive so-called magic mushrooms—as the means to youthful psychedelic adventure—is undergoing a radical transformation. As Michael Pollan reports in this week’s issue of the magazine, doctors at major medical institutions have been using the hallucinogen psilocybin, the mushrooms’ active ingredient, to treat anxiety and “existential distress” in cancer patients. Eddie Marritz, a cinematographer and photographer in remission from small-cell carcinoma, participated in one of New York University’s research studies in late 2013, and continues to feel the benefits of the treatment. Marritz, who had gone into remission before deciding to enroll in the study, takes us through his trip. -maps.org

https://www.change.org/p/donald-trump-d ... medium=sms

[kleinerkiffer84]

Petition ist unterzeichnet.
Eigentlich ein Wahnsinn, dass man überhaupt eine Petition braucht, um Pilze von der Wiese zu entkriminalisieren.
Psilocybin ist ein äusserst wirksames Heilmittel für die Psyche, die ganzen Deppen in der Regierung die etwas anderes behaupten, hatten wohl noch nie echte Probleme.

[Mindlusion]

Die werden dich nicht mehr in die USA rein lassen.











Ich habe die Petition eben unterzeichnet.